Stellar Biotechnologies applies for delisting from TSX Venture Exchange
Port Hueneme-based Stellar Biotechnologies has applied for a voluntary delisting from Canada’s TSX Venture Exchange.
Stellar makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. Common shares of Stellar Biotechnologies stock started trading on the Nasdaq stock exchange Nov. 5.
The company said in a news release its board of directors made the decision because the majority of its shares now trade on the Nasdaq. It also cited the cost and resources required to keep Stellar listed on the TSX Venture Exchange as reasons it asked for the voluntary delisting.
• Contact Philip Joens at [email protected].
